Patents Issued in July 25, 2017
  • Patent number: 9713580
    Abstract: A cosmetic applicator for providing a natural looking cosmetic benefit. The cosmetic applicator includes a substrate and a solid, transferrable cosmetic composition disposed on the substrate. The cosmetic composition is configured as a multitude of dots arranged in a discontinuous stochastic pattern. The cosmetic composition comprises a colorant and an adhesive and in some instances has an L* value of from about 30 to 80, a c* value of from about 15 to 50, and an h* value of from about 30 to 80.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: July 25, 2017
    Assignee: The Procter & Gamble Company
    Inventors: Jorge Max Sunkel, Karen Kay Kalla, Larry Wayne Marshall, Jr.
  • Patent number: 9713581
    Abstract: A magnetic powder to be included in a cosmetic agent being removable by a magnetic attraction force from the cosmetic agent applied to the skin. The magnetic powder comprises a ferromagnetic ferrite, a mean volume particle diameter of 50 to 75 ?m when determined from a particle size distribution obtained by a laser diffraction scattering method, a content of particles with a particle diameter of less than 37 ?m of 15% by mass or less, and a content of particles with a particle diameter of 105 ?m or more of 5% by mass or less. The magnetic powder preferably has a saturation magnetization of 80 Am2/kg or more.
    Type: Grant
    Filed: March 18, 2014
    Date of Patent: July 25, 2017
    Assignee: MTG Co., Ltd.
    Inventors: Tsuyoshi Matsushita, Hiromichi Kobayashi
  • Patent number: 9713582
    Abstract: A multi-layered cosmetic composition suitable for topical application is provided. The composition comprises an oil layer comprising at least about 5%, by weight of the composition, of natural oil; and an aqueous layer, comprising at least about 0.01%, by weight of the composition, of a polymer selected from the group consisting of a polysaccharide, sodium hyaluronate, or a combination thereof. The multi-layered cosmetic composition is free of surfactant.
    Type: Grant
    Filed: April 13, 2015
    Date of Patent: July 25, 2017
    Assignee: The Procter & Gamble Company
    Inventors: Surajit Das, Jayant Eknath Khanolkar
  • Patent number: 9713583
    Abstract: Methods, formulations, and kits for curling and/or preventing damage in the curling of hair are disclosed herein. Hair can be curled by treatment with hydroxide-containing agents, in combination with one or more active agents, without the need for thiol-based or peroxide-based agents. The active agent can be applied simultaneously with the hydroxide-containing agent, to impart curl to the hair. They may be applied as a combined formulation or as separate formulations applied simultaneously. Use of the active agent along with a hydroxide-containing agent can be used to control the level of curl imparted to hair, as compared to the natural amount of curl, if any, in the untreated hair.
    Type: Grant
    Filed: September 30, 2016
    Date of Patent: July 25, 2017
    Assignee: Liqwd, Inc.
    Inventors: Eric D. Pressly, Craig J. Hawker
  • Patent number: 9713584
    Abstract: Provided is an internal olefin sulfonate composition which is capable of exerting good foamability together with good volume of foam, foaming speed, foam dissipation property, foam quality, foam durability in the presence of sebum, and volume of foam in the presence of sebum at high levels, and a cleansing composition containing the same. The internal olefin sulfonate composition of the present invention comprises (A) an internal olefin sulfonate having 16 carbon atoms and (B) an internal olefin sulfonate having 18 carbon atoms, wherein a mass content ratio (A/B) of component (A) to component (B) is from 75/25 to 90/10, and wherein a mass ratio (hydroxy form/olefin form) of a content of a hydroxy form in the internal olefin sulfonate of the component (A) and the component (B) to a content of an olefin form in the internal olefin sulfonate of the component (A) and the component (B) is from 75/25 to 100/0.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: July 25, 2017
    Assignee: KAO CORPORATION
    Inventors: Yohei Yoshikawa, Yoshinori Mitsuda, Hiroshi Hori, Yoshifumi Nishimoto, Yasuhiro Doi
  • Patent number: 9713585
    Abstract: Adhesion of a composition for nail coatings be improved by addition of a polyhedral oligomeric silsesquioxane (POSS). Nail coating compositions that benefit from the addition of a POSS include enamels, reactive composition such as those containing acrylates, solventless compositions and water-based compositions.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: July 25, 2017
    Assignee: CREATIVE NAIL DESIGN, INC.
    Inventors: David Valia, Jamie Ellis
  • Patent number: 9713586
    Abstract: An oral care composition comprising a diluted sodium calcium alginate gel, wherein the oral care composition is a toothpaste, a gel, a mouthwash or a mouthrinse.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: July 25, 2017
    Assignee: Colgate-Palmolive Company
    Inventors: Manying Shi, Xiaojing Lv, Rolando Plata, Zhuoxing Zhang
  • Patent number: 9713587
    Abstract: A skin smoothing composition that has from about 0.5 to about 10%, by weight, of an interpenetrating polymer that is a co-polymer of polyurethane and a polyacrylic polymer. The composition further contains from about 0.1% to about 5%, by weight, of a thickener made from homopolymers of acrylic acid crosslinked with a cross linker selected from the group consisting of an allyl ether pentaerythritol, allyl ether of sucrose, allyl ether of propylene and mixtures thereof. And from about 10 to 98% water.
    Type: Grant
    Filed: September 25, 2015
    Date of Patent: July 25, 2017
    Assignee: The Procter & Gamble Company
    Inventor: Timothy Roy Nijakowski
  • Patent number: 9713588
    Abstract: The present invention relates to a nail polish composition comprising: at least one high gloss film forming agent chosen from a styrene maleic anhydride copolymer; at least one co-film forming agent chosen from an epoxy resin; at least one reactive agent chosen from a combination of a polyalkyleneamine and a polyurethane, at least one polyalkyleneamine, and at least one alkoxysilane comprising at least one solubilizing functional group; at least one solvent chosen from at least one volatile solvent and water; optionally, at least one plasticizer; and optionally, at least one colorant, wherein the composition does not require use of nitrocellulose and can be used to makeup or protect nails.
    Type: Grant
    Filed: October 31, 2011
    Date of Patent: July 25, 2017
    Assignee: L'OREAL
    Inventors: Hy Si Bui, Chunhua Li, Sarah Fairneny, Luis Ortega, Mohamed Kanji, Ram Hariharan
  • Patent number: 9713589
    Abstract: The present invention relates to methods for the preparation of an aerosol. More specifically the present invention provides methods for the preparation of an aerosol of immunoglobulin single variable domains wherein the amount of aggregate formation is significantly reduced. The invention further provides aerosols prepared by the methods of the invention, as well as compositions for use in the methods of the invention. The invention further relates to methods for the preparations of such compositions, to containers, kits and aerosol delivery systems comprising such compositions and to uses of the same.
    Type: Grant
    Filed: February 11, 2011
    Date of Patent: July 25, 2017
    Assignee: Ablynx N.V.
    Inventors: Erik Depla, Mauro Sergi, Peter Casteels
  • Patent number: 9713590
    Abstract: The present invention relates to a method for the treatment of pain and inflammation. In particular, the present invention relates to a method for the treatment of musculo-skeletal and connective tissue pain/inflammations. Further, the invention relates to reducing the incidence and seventy of adverse events resulting from administration of diclofenac. The method comprises administration of a topical pharmaceutical composition of diclofenac or its salts.
    Type: Grant
    Filed: January 5, 2012
    Date of Patent: July 25, 2017
    Assignee: CADILA HEALTHCARE LIMITED
    Inventors: Ravindra Mittal, Sunilendu Bhushan Roy, Jay Shantilal Kothari, Shafiq Sheikh
  • Patent number: 9713591
    Abstract: The present disclosure provides a composition of matter comprising liposomes encapsulating in their intraliposomal aqueous compartment at least one active agent, the liposomes having a diameter of at least 200 nm and being embedded in a water insoluble, water absorbed cross-linked polymeric matrix. In one embodiment, the composition of matter is held within an aqueous medium, preferably being in iso-osmotic equilibrium with the intraliposomal aqueous compartments of the liposomes.
    Type: Grant
    Filed: October 11, 2009
    Date of Patent: July 25, 2017
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem, LTD.
    Inventors: Yechezkel Barenholz, Rivka Cohen
  • Patent number: 9713592
    Abstract: The present invention relates to an oral pulse release pharmaceutical composition, which comprises a polymer matrix core, wherein at least one pharmaceutically active ingredient is distributed within the core and on the outer surface of the core. Amphetamine salts, among a number of other pharmaceutically active ingredients, can be formulated as a pharmaceutical composition described herein. The present invention also provides a method for preparing an immediate release component on a solid pharmaceutical formulation.
    Type: Grant
    Filed: March 22, 2006
    Date of Patent: July 25, 2017
    Assignee: MALLINCKRODT LLC
    Inventors: Ashwini Gadre, Mark R. Benmuvhar, Brian Kai-Ming Cheng, Vishal K. Gupta, Cliff J. Herman
  • Patent number: 9713593
    Abstract: Provided is an alkyl cellulose excellent in formability when added even in a small amount and not causing marked delay in disintegration; a solid preparation including it; and a method for producing the solid preparation. More specifically, provided is an alkyl cellulose for use in tableting, the alkyl cellulose having a specific surface area of from 0.5 to 10.0 m2/g as measured by BET method and a solid preparation including the alkyl cellulose. Also provided is a method for producing the alkyl cellulose, including the steps of: bringing pulp into contact with an alkali metal hydroxide solution to obtain alkali cellulose, reacting the alkali cellulose with an etherifying agent to obtain a first alkyl cellulose, pulverizing the first alkyl cellulose, and depolymerizing the pulverized first alkyl cellulose through hydrolysis with an acid catalyst or through oxidative decomposition with an oxidant to obtain a second alkyl cellulose.
    Type: Grant
    Filed: October 12, 2015
    Date of Patent: July 25, 2017
    Assignee: Shin-Etsu Chemical Co., Ltd.
    Inventors: Takuya Yokosawa, Naosuke Maruyama
  • Patent number: 9713594
    Abstract: An exemplary method comprises providing a spray-dried dispersion comprising particles, the particles comprising an active agent and a polymer, the dispersion particles having an average particle diameter of less than 50 ?m. An ordered mixture is formed by high-shear mixing the dispersion with a powdered glidant, wherein the average particle diameter of the glidant is less than or equal to one fifth the average particle diameter of the dispersion after high-shear mixing. The dosage forms are formed by at least one of directly compressing the ordered mixture to form a tablet and encapsulating the ordered mixture to form a capsule.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: July 25, 2017
    Assignee: Bend Research, Inc.
    Inventors: Jason A. Everett, Randy J. Wald, Sanjay Konagurthu
  • Patent number: 9713595
    Abstract: Sustained-release compositions wherein a water-soluble physiologically active peptide is substantially uniformly dispersed in a microcapsule comprised of a lactic acid polymer or a salt thereof, and the physiologically active substance is contained in an amount of 15 to 35 wt/wt % to the total microcapsules and weight-average molecular weight (Mw) of the lactic acid polymer is about 11,000 to about 27,000, which is characterized by having a high content of the physiologically active substance, and suppression of the initial excessive release within one day after the administration and a stable drug sustained-release over a long period of time, and method for producing the same.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: July 25, 2017
    Assignee: Takeda Pharmaceuticals Company Limited
    Inventors: Tomomichi Futo, Kazuhiro Saito, Tetsuo Hoshino, Masuhisa Hori
  • Patent number: 9713596
    Abstract: Methods for treating excess pigmentation, including treatment of post inflammatory hyperpigmentation (PIH), are disclosed. The disclosed methods comprise administration of a composition comprising bakuchiol substantially free of furanocoumarins to a mammal. Compositions comprising bakuchiol and methods for their preparation are also disclosed.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: July 25, 2017
    Assignee: Unigen, Inc.
    Inventors: Mei Feng Hong, Qi Jia, Lidia Alfaro Brownell
  • Patent number: 9713597
    Abstract: An aqueous pharmaceutical solution composition comprising between about 20 mg/ml to about 100 mg/ml of a radioprotective ?,?-unsaturated aryl sulfone, a cosolvent comprising polyethylene glycol (PEG), polypropylene glycol, polyglycerol, DMA, propylene glycol, glycerol, ethanol, sorbitol, isopropyl alcohol, or a combination thereof in an amount between about 25% and about 90% w/v, and a water soluble Vitamin E derivative, wherein the composition has a pH within the range of about 7.0 to about 9.5.
    Type: Grant
    Filed: May 15, 2015
    Date of Patent: July 25, 2017
    Assignee: ONCONOVA THERAPEUTICS, INC.
    Inventor: Manoj Maniar
  • Patent number: 9713598
    Abstract: Insulin resistance biomarkers and related methods of using the biomarkers are provided. The biomarkers may be blood biomarkers and include C-peptide, Insulin-Like Growth Factor-Binding Protein 2 (IGFBP-2), and Leptin. Also provided is a method of reducing the effect of prolonged physical inactivity on insulin resistance in a subject who is experiencing prolonged physical inactivity, or who is expected to experience prolonged physical inactivity in the near future.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 25, 2017
    Assignee: ABBOTT LABORATORIES
    Inventors: Menghua Luo, Suzette Pereira, Neile Edens, Gerard Davis, Susan Gawel, Raj Chandran
  • Patent number: 9713599
    Abstract: The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The invention also relates to kits for treatment and/or prevention of ischemic lesions, comprising an effective amount of Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: July 25, 2017
    Assignee: United Therapeutics Corporation
    Inventor: Michael Wade
  • Patent number: 9713600
    Abstract: Methods for detecting risks for and/or causes of metabolic syndrome or hyperferritinemia in accordance with several embodiments can include the step of measuring the level of heptadecanoic acid in a blood sample of a subject. The methods of several embodiments can further include the step of deeming the subject as having or being at risk of metabolic syndrome if the amount of heptadecanoic acid is below 0.4% of all fatty acids in the sera or plasma. The methods for treating metabolic syndrome or hyperferritinemia according to several embodiments can also include the step of administering a daily dose of heptadecanoic acid to a subject suffering from metabolic syndrome or hyperferritinemia for a period of time from three weeks to twenty-four weeks, wherein the minimum daily dose comprises about 3 mg per lb (or 6 mg per kg) of body weight.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: July 25, 2017
    Assignee: The United States of America, as Represented by the Secretary of the Navy
    Inventor: Stephanie Venn-Watson
  • Patent number: 9713601
    Abstract: The present invention relates to new ingenol derivative compounds for inhibiting cancer cell viability and treating cancer. In other aspects, the invention relates to a pharmaceutical composition, a medicament, methods for treating cancer, and a dosage form.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: July 25, 2017
    Assignee: AMAZÔNIA FITOMEDICAMENTOS LTDA
    Inventors: Luiz Francisco Pianowski, Everardo Ferreira Telles
  • Patent number: 9713602
    Abstract: The present invention relates to a method for increasing the oxygen release efficiency of a hemoglobin-based blood substitute by using a phthalide compound, comprising the steps of: administering to a subject in need thereof the phthalide compound or co-administering to the subject in need thereof the phthalide compound along with the hemoglobin-based blood substitute, wherein the phthalide compound has an effect of increasing the oxygen release efficiency of the hemoglobin-based blood substitute, wherein the hemoglobin-based blood substitute can be fetal hemoglobin (HbF) or other Hb variants retaining two native ? subunits. The phthalide compound is used to substitute for or cooperate with 2,3-BPG, to play a role of a 2,3-BPG substitute, to act on the hemoglobin-based blood substitute to effectively substitute the function of normal hemoglobin in releasing oxygen to tissue cells, in order to maintain the cellular oxygenation level within a normal range.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: July 25, 2017
    Assignee: NATIONAL SUN YAT-SEN UNIVERSITY
    Inventors: Chia-Chen Wang, Wei-Ren Chen
  • Patent number: 9713603
    Abstract: Method of treating endometriosis and related indications, comprising the administration of Pro-EGCG, a synthetic and derivative product of epigallocatechin-3-gallate [(?)-EGCG]. Use of Pro-EGCG in the manufacture of a medicament for treating endometriosis and related indications. Pro-EGCG for use in the treatment of endometriosis and related indications.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: July 25, 2017
    Assignees: The Hong Kong Polytechnic University, The Chinese University of Hong Kong
    Inventors: Tak-Hang Chan, Chi-Chiu Wang
  • Patent number: 9713604
    Abstract: The invention provides non-irritating, stable topical compositions including at least Vitamin C, Vitamin E and a polyphenol antioxidant. Such compositions can be used to facilitate the prevention or treatment of free oxygen, nitrogen, and/or other free radical related skin damage. Also provided are methods for modifying free radical damage to skin by administering such compositions in an amount sufficient to treat and/or prevent free radical damage to the skin.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: July 25, 2017
    Assignee: ANTEIS SA
    Inventor: Frank Dreher
  • Patent number: 9713605
    Abstract: The present invention relates to a method of preventing or ameliorating the symptoms of arthritis or preventing or ameliorating cartilage destruction or chondrocyte death in a subject suffered from arthritis, comprising administrating the subject an effective amount of an active component selected from a compound, a mixture, and a mycelium prepared from Antrodia cinnamomea.
    Type: Grant
    Filed: November 19, 2012
    Date of Patent: July 25, 2017
    Assignee: Simpson Biotech Co., Ltd.
    Inventors: Wei-Tso Chia, Chia-Chin Sheu
  • Patent number: 9713606
    Abstract: This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.
    Type: Grant
    Filed: December 1, 2015
    Date of Patent: July 25, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Ralf Anderskewitz, Florian Binder, Matthias Grauert, Marc Grundl, Peter Wilhelm Haebel, Thorsten Oost, Alexander Pautsch, Stefan Peters, Viktor Vintonyak
  • Patent number: 9713607
    Abstract: The present invention is based on the discovery that certain fermentation products of the marine actinomycete strains CNB392 and CNB476 are effective inhibitors of hyperproliferative mammalian cells. The CNB392 and CNB476 strains lie within the family Micromonosporaceae, and the generic epithet Salinospora has been proposed for this obligate marine group. The reaction products produced by this strain are classified as salinosporamides, and are particularly advantageous in treating neoplastic disorders due to their low molecular weight, low IC50 values, high pharmaceutical potency, and selectivity for cancer cells over fungi.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: July 25, 2017
    Assignee: The Regents of the University of California
    Inventors: William Fenical, Paul Jensen, Tracy Mincer, Robert H. R. Feling
  • Patent number: 9713608
    Abstract: The invention relates to the treatment of actinic keratosis on the trunk (except chest) or Extremities with ingenol 3-(3,5-diethylisoxazole-4-carboxylate).
    Type: Grant
    Filed: October 27, 2014
    Date of Patent: July 25, 2017
    Assignee: LEO Laboratories Limited
    Inventors: Johan Selmer, Kim Mark Knudsen
  • Patent number: 9713609
    Abstract: The present invention provides for compositions, methods and kits for regulating energy metabolism. In one aspect, the invention provides for compositions that comprise a combination of (a) branched chain amino acids, such as leucine, and (b) vitamin B6, or any precursors or metabolites of (a) or (b). These combinations may be synergistic and/or effective for reducing weight or adipose volume. In another aspect, the invention provides for methods of regulating energy metabolism by the administration of one or more compositions comprising branched chain amino acids and vitamin B6. The invention also provides for kits comprising compositions of branched chain amino acids and vitamin B6 packaged in an oral dose form with usage instructions.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: July 25, 2017
    Assignee: NuSirt Sciences, Inc.
    Inventors: Michael Zemel, E. Douglas Grindstaff, II
  • Patent number: 9713610
    Abstract: The invention relates to medicine and pharmacology, more particularly to drugs, and even more particularly to pharmaceutical compositions for treating gastroesophageal reflux disease (GERD). The pharmaceutical composition for treating GERD contains at least one proton pump inhibitor (PPI) and at least one prebiotic. Also claimed is a method for treating gastroesophageal reflux disease in which it is not necessary to eradicate the presence of H. pylori in order to prevent the risks associated with the translocation of said bacteria from the antrum to the body of the stomach. The composition provides for prevention of the translocation of H. pylori by means of the colonization of the antrum by lactobacilli and the concurrent inhibition of H. pylori during PPI therapy. This makes it possible to dispense with the need to detect the bacteria and carry out a course of eradication therapy. The safety of long-term PPI therapy is increased.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: July 25, 2017
    Inventors: Alexander Vladimirovich Dikovskiy, Leonid Borisovich Lazebnik, Dmitry Stanislavovich Bordin, Elena Valentinovna Belova
  • Patent number: 9713611
    Abstract: The present invention relates to a composition comprising pharmaceutical active ingredients which are susceptible to, or have potential for, abuse. The invention provides an oral pharmaceutical composition comprising a first population of beads and a second population of beads. The first bead population comprises a pharmaceutically active ingredient susceptible to, or having the potential for, abuse. The second bead population comprises a gelling agent and a coating substantially surrounding the gelling agent, but containing no pharmaceutically active ingredient. The first bead population and the second bead population are physically separable, but visually indistinguishable to the naked eye. Upon ingress of water into the second population of beads, the gelling agent is caused to swell forming a viscous mass inhibiting or preventing the extraction of the active ingredient.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: July 25, 2017
    Assignee: Recro Gainesville, LLC
    Inventors: Gurvinder Singh Rekhi, Richard Sidwell
  • Patent number: 9713612
    Abstract: The present invention relates to compounds as inhibitor of WNT signal transduction pathway, as well as a composition comprising the same. Further, the present invention relates to the use of the compounds in the treatment of cancer.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: July 25, 2017
    Assignee: CUREGENIX, INC.
    Inventor: Songzhu An
  • Patent number: 9713613
    Abstract: The present invention relates to methods of treating a disease related to cell hyper-proliferation via administration of a therapeutically effective amount of a compound having a general tripartite structure A-B-C. In the tripartite structure A, B, and C are identical or non-identical structures, for example, but not limited to, heterocyclic, phenyl or benzyl ring structures with or without substitutions and are described in detail herein. The methods may utilize particular compounds, for example, having a piperidinyl, a pyrrolinyl or pyridinyl A ring, a thiazole B ring, and a phenyl C ring which may be further substituted independently.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: July 25, 2017
    Inventors: Motonari Uesugi, Salih J. Wakil, Lutfi Abu-Elheiga, Mizuki Watanabe
  • Patent number: 9713614
    Abstract: The invention relates to the combined use of a PDE4 inhibitor with a HMG-CoA reductase inhibitor for the prevention and curative treatment of an inflammatory pulmonary disease.
    Type: Grant
    Filed: May 22, 2015
    Date of Patent: July 25, 2017
    Assignee: ASTRAZENECA AB
    Inventors: Stefan-Lutz Wollin, Andrea Wohlsen, Clemens Braun, Degenhard Marx
  • Patent number: 9713615
    Abstract: Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone derivatives represented by formula (I), pharmacologically acceptable salts thereof, and compositions containing such compounds are described. Methods for treating hyperproliferative disorders by administering the compounds are also described. 1,2,3,4-tetrahydroisoquinoline derivatives for making tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds are also described.
    Type: Grant
    Filed: October 21, 2015
    Date of Patent: July 25, 2017
    Assignee: Rexahn Pharmaceuticals, Inc.
    Inventors: Young Bok Lee, Jae Min Kim, Deog Joong Kim, Chang-Ho Ahn
  • Patent number: 9713616
    Abstract: Compositions comprising a calcium salt of L-leucovorin may be prepared that have a higher concentration of L-leucovorin than may be prepared using racemic leucovorin under similar conditions. Thus, some pharmaceutical compositions described herein may comprise a calcium salt of L-leucovorin at a relatively high concentration, such as at least about 15 mg/mL. Such a composition may be a stable aqueous solution, and may have near physiological pH, such as about 6 to about 8. Some pharmaceutical compositions may be substantially free of D-leucovorin, and may contain either: a) no EDTA, or b) less than about 1 mg/ml of EDTA. These compositions may be prepared, for example, by sonicating a mixture comprising the solid calcium salt of L-leucovorin and water. In some compositions, a calcium salt of L-leucovorin may be sufficiently soluble that it does not precipitate when it is injected.
    Type: Grant
    Filed: August 6, 2013
    Date of Patent: July 25, 2017
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Pramod Kumar Gupta, Bahman Shimiaei, Shaofeng Xie
  • Patent number: 9713617
    Abstract: Described herein is the Bruton's tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: December 21, 2016
    Date of Patent: July 25, 2017
    Assignee: Pharmacyclics LLC
    Inventors: Norbert Purro, Mark Stephen Smyth, Erick Goldman, David D. Wirth
  • Patent number: 9713618
    Abstract: The present invention relates to the use of a certain DPP-4 inhibitor for modifying food intake and regulating food preference.
    Type: Grant
    Filed: May 21, 2013
    Date of Patent: July 25, 2017
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thomas Klein, Michael Mark
  • Patent number: 9713619
    Abstract: The invention relates to classes of pharmaceutically-active heterocyclic compounds and pharmaceutically acceptable salts, and hydrates thereof, and compositions comprising the same. The invention also relates to methods for treating or preventing a disease or disorder, which comprises administering a therapeutically or prophylactically effective amount a compound described herein.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: July 25, 2017
    Assignee: Cerenis Therapeutics Holding SA
    Inventors: Daniela Carmen Oniciu, Jean-Louis Henri Dasseux, Ronald Barbaras, Oleg Gennadievich Rodin, Anna Rzepiela
  • Patent number: 9713621
    Abstract: The present invention provides a composition and method for treating endometriosis which generally, comprises a mixture of anabolic steroids and the administration of same. The first anabolic steroid used is stanozolol used in conjunction with nandralone. The composition is preferably deployed an as injectable liquid suspension. It is also possible to deploy the steroids used herein as an oral administration of the stanozolol alone with an injection of nandralone weekly or as a daily topical nandralone cream.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: July 25, 2017
    Inventor: Edward Lichten
  • Patent number: 9713622
    Abstract: The present invention relates to a pharmaceutical composition for treating the human immunodeficiency virus (HIV) in humans, including three or four active principles selected as: a nucleoside reverse transcriptase inhibitor (NRTI) selected from lamivudine and emtricitabine; a nucleoside or nucleotide reverse transcriptase inhibitor (NRTI) selected from didanosine, abacavir and tenofovir; and the combination of a boosted or unboosted protease inhibitor (PI) selected from lopinavir, fosamprenavir, atazanavir and darunavir; or an non-nucleoside reverse transcriptase inhibitor (NNRTI) selected from efavirenz and etravirine; or an integrase inhibitor; for daily administration to said human being one to four days per week.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: July 25, 2017
    Assignee: UNIVERSITÉ VERSAILLES SAINT-QUENTIN-EN-YVELINES
    Inventor: Jacques Leibowitch
  • Patent number: 9713623
    Abstract: The present invention provides compounds of Formula I or Formula II: wherein: T, V, W, Y and Z are each independently selected from the group of substituents described herein, and X is a linker as further described herein. The present invention further provides compositions and conjugates including the compounds as well as methods of using these compounds including, but not limited to, methods of preventing, treating and/or diagnosing genetic disorders, such as muscular dystrophy, or non-genetic disorders as described herein.
    Type: Grant
    Filed: March 31, 2015
    Date of Patent: July 25, 2017
    Assignee: The Charlotte-Mecklenburg Hospital Authority
    Inventors: Mingxing Wang, Qi Lu
  • Patent number: 9713624
    Abstract: The synthesis of rutin nanotubes includes the steps of providing rutin powder; mixing the rutin powder with a solvent mixture of methanol, dimethyl sulfoxide, and hydrochloric acid to prepare a rutin solution; adding the rutin solution to boiling water dropwise; maintaining the rutin solution and water under ultrasonic conditions at room temperature for about 20 minutes; continuously stirring the solution until rutin nanoparticles are formed; and isolating the rutin nanotubes by centrifugation. A method of controlling the metastatic activity of cancer cells includes administering an effective amount of rutin nanotubes and nanoparticles prepared as described above to a site of metastatic activity in a mammal.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: July 25, 2017
    Assignee: King Saud University
    Inventors: Manal Ahmed Gasmelseed Awad, Mohamed Mahmoud Hafez Ahmed, Othman A. Al-Shabanah, Zeinab Korany Mohamed Hassan
  • Patent number: 9713625
    Abstract: Described herein are methods for diagnosing ovarian cancer. In particular, certain microRNAs are useful to the response to chemotherapy of ovarian cancer patients.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: July 25, 2017
    Assignee: The Ohio State University
    Inventors: Carlo M. Croce, Andrea Vecchione
  • Patent number: 9713626
    Abstract: Pharmaceutical compositions comprising an mRNA-loaded nanoparticle, wherein the mRNA is an in vitro transcribed mRNA and has a coding sequence at least 80% identical to SEQ ID NO: 3, and wherein the mRNA encodes a human cystic fibrosis transmembrane conductance regulator (CFTR) protein comprising the amino acid sequence of SEQ ID NO:1 are provided. The present invention is particularly useful for treating cystic fibrosis.
    Type: Grant
    Filed: October 6, 2015
    Date of Patent: July 25, 2017
    Assignees: RaNA Therapeutics, Inc., Ethris GmbH
    Inventors: Michael Heartlein, Braydon Charles Guild, Frank DeRosa, Carsten Rudolph, Christian Plank, Lianne Smith
  • Patent number: 9713627
    Abstract: The present invention provides pathogen-inactivated red blood cell compositions suitable for infusion into a subject.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: July 25, 2017
    Assignee: Cerus Corporation
    Inventors: Naheed Mufti, Anna Erickson, Anne North
  • Patent number: 9713628
    Abstract: Restoration or increase of inhibitory interneuron function in vivo is achieved by transplantation of MGE cells into the brain. Compositions containing MGE cells are provided as are uses to treat various diseases characterized by abnormal inhibitory interneuron function or in cases where increase inhibition may ameliorate neural circuits that are abnormally activated.
    Type: Grant
    Filed: September 8, 2015
    Date of Patent: July 25, 2017
    Assignee: The Regents of the University of California
    Inventors: Scott C. Baraban, John L. Rubenstein, Arturo Alvarez-Buylla
  • Patent number: 9713629
    Abstract: The present invention provides novel compositions comprising multipotent cells or microvascular tissue, wherein the cells or tissue has been sterilized and/or treated to inactivated viruses, and related methods of using these compositions to treat or prevent tissue injury or disease in an allogeneic subject.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: July 25, 2017
    Assignee: MicroVascular Tissues, Inc.
    Inventors: Dale R. Peterson, Ralph-Heiko Mattern, Corey Wilson-Wirth, Kevin L. Ohashi
  • Patent number: 9713630
    Abstract: The disclosure provides oral compositions and methods of using such compositions in treating subjects infected with one or more hepatic disorders. The compositions include lysates or cell wall extracts of one or more gram positive bacteria, exhibit particular activity against hepatitis C virus (HCV), and may be useful in treating those infected with HCV as well as other hepatic diseases or disorders. Also described are methods of treating a hepatic disease or disorder by administering a therapeutically effective amount of at least one therapeutically active agent capable of upregulating or downregulating the Complement system pathway, wherein the therapeutically active agent enhances the formation of one or more convertase enzymes.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: July 25, 2017
    Assignee: Labyrinth Holdings, LLC
    Inventor: Elizabeth McKenna